Emcure Pharmaceuticals Ltd Q2 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/vkticr6qvkr38f1j76jjdg54.pdf

Key Takeaways


India Business: Recovery & Trajectory

Mehta: "in my 30 years of association with the domestic market, once the economic growth picks up, normally, I have seen the growth of the pharma industry is 1.5x that of the economic growth that we have. So, if you are growing at 8%, 12% is granted, it is going to happen, 11%, 12%."

International: Geography Mix & Drivers


Product Pipeline & Key Assets

Mehta: "It's not really going to happen in a day, but we obviously see ourselves a long-term player in this particular market and things are happening in the right direction. It's not earth-shattering the way it was felt some time back, but we are right there."

Margins & Cost Structure

Thapar: "on the one hand, we benefited from some favourable currency impact. On the other side, I think some of these costs are wiping out a big chunk, if not most of those gains. So that's why, I think, overall, our gross margin impact has been relatively muted. But certainly, we have been seeing, in many cases, some rising input costs."

Balance Sheet & Capital Allocation


Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growthExceed 20% (raised from mid-teens)FY27 full year
EBITDA margin improvementUpper end of 75–100 bps rangeFY27 full year
Domestic organic growthAt or above industry growthBy FY27 exit
Zuventus growthIn line with IPM growthBy end of FY27
R&D spendWithin 4%–5% of revenueFY27 full year
Net debtBecome net cashBy end of FY28
Amphotericin B emerging market launchesAt least a couple of markets launchingNext half (H2 FY27)
Semaglutide Canada filingFile in next few monthsThis fiscal (FY27)
Manufacturing capacityFacilities able to cater without restrictionNext 18–24 months
ARV share of RoW50%–55% of RoW salesFY27 full year

Key Metrics

MetricQ2 FY27
Revenue from operations₹2,820 cr, up 24.3% YoY and 9.3% QoQ
India revenue₹1,155 cr, up 12% YoY; organic growth 10% vs 6% in Q1
International revenue₹1,665 cr, up 34.5% YoY, 59% of total revenue
Europe revenue₹604 cr, up 36% YoY
Canada revenue₹431 cr, up 24% YoY
Rest of World revenue₹630 cr, up 41% YoY
EBITDA₹575 cr, up 31% YoY
EBITDA margin20.4%, expanded ~100 bps YoY and ~70 bps QoQ
PAT₹325 cr, up 29% YoY; PAT margin 11.5%, improvement of 45 bps
Gross margin59.5%, QoQ improvement of ~110 bps
R&D spend₹111 cr, ~4% of revenue from operations
Net debt₹1,317 cr as of September, increase of ₹263 cr over March '26
H1 acquisition-related payouts₹551 cr, including final Canada payout, minority stake in Genova, UK product portfolio payment
Overall constant currency growth18.5%; international constant currency growth ~24%
ARV share of Rest of World revenue~50%, down from 67% in Q1
Full-year FY27 revenue growth guidanceExceed 20%, raised from mid-teens earlier
Full-year FY27 EBITDA margin guidanceUpper end of 75–100 bps improvement range